Faculty Members

IMPORTANT NOTE: Virtual meeting time indicated in the scientific program is expressed as GMT Time Zone. Please check time as per your timezone

Meltem Olga Akay
Indolent Lymphomas
*Scientific Chair
Start Time
19:15
End Time
20:45
LYMPHOMA
*BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTO-SCT IN HIGH-RISK HODGKIN’S LYMPHOMA: MULTI-CENTER RETROSPECTIVE STUDY
Start Time
22:00
End Time
23:00
Yalım Akın
PRECLINIC/GENETIC
*KILLER IMMUNOGLOBULIN LIKE HAPLOTYPE BB IS OBSERVED MORE FREQUENTLY AMONG MYELOMA CASES COMPARED TO HEALTHY CONTROLS
Start Time
22:00
End Time
23:00
Othman Al - Sawaf
Chronic Lymphocytic Leukemia
*Modelling of Response Pattern and Cloned Evolution of CLL
Start Time
11:30
End Time
13:00
İnci Alacacıoğlu
Acute Myeloid Leukemia
*Scientific Chair
Start Time
09:30
End Time
11:00
Neslihan Andıç
Opening Ceremony
Start Time
13:30
End Time
13:45
Muhlis Cem Ar
3rd Istanbul Immunohematology Summit
*Opening Remarks
Start Time
08:00
End Time
08:15
Opening Ceremony
Start Time
13:30
End Time
13:45
PRECLINIC/GENETIC
*Scientific Chair
Start Time
22:00
End Time
23:00
Mutlu Arat
MULTIPLE MYELOMA
*Scientific Chair
Start Time
22:00
End Time
23:00
Önder Arslan
Janssen Satellite Symposium
*Breakthrough CLL Disease Control in Relapsed & Refractory Settings: Long Term Ibrutinib Outcomes
Start Time
16:45
End Time
17:30
Acute Lymphoblastic Leukemia
*Scientific Chair
Start Time
18:00
End Time
19:30
Mürüvvet Seda Aydın
LEUKEMIA/LYMPHOMA
*DIAGNOSTIC CHALLENGES AND CONSEQUENT THERAPEUTIC DILEMMAS ENCOUNTERED IN CLASSIFYING ACUTE MYELOID LEUKEMIAS
Start Time
22:00
End Time
23:00
Berrin Balık Aydın
PRECLINIC/GENETIC
*MYD88 EXPRESSION IN PRIMARY AND SECONDARY CNS LYMPHOMAS
Start Time
22:00
End Time
23:00
INFECTION/QUALITY OF LIFE
*QUALITY OF LIFE MEASURES OF THE PATIENTS WHO ARE DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES AND TIME EFFECT ON PARAMETERS
Start Time
22:00
End Time
23:00
LEUKEMIA/LYMPHOMA
*PERSISTENT POLYCLONAL B-CELL LYMPHOCYTOSIS WITH BINUCLEATED LYMPHOCYTES (PPBL)
Start Time
22:00
End Time
23:00
Guldidar Basmacı
LYMPHOMA
*EVALUATION OF PD-1/ PD-L1 EXPRESSION, TUMOR MICROENVIRONMENT AND PROGNOSTIC FACTORS IN DIFFUSE LARGE B CELL LYMPHOMA
Start Time
22:00
End Time
23:00
Mehmet Baysal
MULTIPLE MYELOMA
*COMPARISON OF CANCER AND AGING RESEARCH GROUP SCORE (CARG) AND COMORBIDITY INDEX SCORES IN MULTIPLE MYELOMA PATIENTS
Start Time
22:00
End Time
23:00
Meral Beksaç
Monoclonal Antibody Directed Immunotherapies
*Scientific Chair
Start Time
11:30
End Time
12:45
Janssen Satellite Symposium
*Scientific Chair
Start Time
16:00
End Time
16:45
Nadiia Bilous
PRECLINIC/GENETIC
*THE IGLV3-21 LIGHT CHAIN ANALYSIS IN IR-RELATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
Start Time
22:00
End Time
23:00
Nicolas Boissel
Acute Lymphoblastic Leukemia
*Current Status and Future Prospects in T-ALL
Start Time
18:00
End Time
19:30
Paul Bröckelmann
Hodgkin Lymphoma
*Firstline Treatment of HL
Start Time
14:45
End Time
16:15
Lars Bullinger
Acute Myeloid Leukemia
*Molecular Heterogeneity and Clonal Evolution of AML
Start Time
09:30
End Time
11:00
Ferda Can
LEUKEMIA/LYMPHOMA
*GIANT MASS IN THE EYELID: T CELL LYMPHOMA
Start Time
22:00
End Time
23:00
Güldane Cengiz Seval
MULTIPLE MYELOMA
*POSTINDUCTION FDG-PET IMAGING IMPROVES THE IMPACT OF BIOCHEMICAL RESPONSE ASSESSMENT ON TRANSPLANT OUTCOME
Start Time
22:00
End Time
23:00
Mark Cragg
Monoclonal Antibody Directed Immunotherapies
*Beyond Naked Antibodies
Start Time
11:30
End Time
12:45
Ahmet Muzaffer Demir
Janssen Satellite Symposium
*Scientific Chair
Start Time
16:45
End Time
17:30
Gülderen Demirel
COVID-19 and Immunity
*Immunological Basis COVID- 19 Infection and Immunoreactivity
Start Time
08:30
End Time
09:45
Fuat Hulusi Demirelli
Monoclonal Antibody Directed Immunotherapies
*Check Point Inhibitors
Start Time
11:30
End Time
12:45
Fatih Demirkan
Chronic Lymphocytic Leukemia
*Scientific Chair
Start Time
11:30
End Time
13:00
Janssen Satellite Symposium
*How Biology is Informing Treatment Decisions in Firstline CLL ?
Start Time
16:45
End Time
17:30
Günnur Deniz
Pediatric Leukemias-I
*Towards shaping a high-quality network of FLOW-MRD labs in Turkey
Start Time
14:00
End Time
15:30
Anıca Dıvac
INFECTION/QUALITY OF LIFE
*EFFICACY OF ANTI-IL-6 ANTIBODY IN THREE PATIENTS WITH COVID-19 INFECTION AND MULTIPLE MYELOMA
Start Time
22:00
End Time
23:00
Hartmut Döhner
Acute Myeloid Leukemia
*Scientific Chair
Start Time
09:30
End Time
11:00
Acute Myeloid Leukemia
*Combining New Agents with “3+7“ Chemotherapy in Fit Patients
Start Time
09:30
End Time
11:00
Martin Dreyling
Aggressive Lymphomas
*Scientific Chair
Start Time
20:00
End Time
21:30
Aggressive Lymphomas
*Mantle Cell Lymphoma
Start Time
20:00
End Time
21:30
Michael Dworzak
Pediatric Leukemias-I
*Scientific Chair
Start Time
14:00
End Time
15:30
Pediatric Leukemias-I
*Advancements of the I-BFM FLOW Network: Innovative Solutions for Diagnosis and MRD Assessment in Acute Leukemias
Start Time
14:00
End Time
15:30
Dennis Eichenauer
Hodgkin Lymphoma
*Update on NLPHL
Start Time
14:45
End Time
16:15
Hermann Einsele
Off the Shelf Cellular Therapies
*CAR-T Cells
Start Time
10:00
End Time
11:15
Elçin Erdoğan Yücel
LYMPHOMA
*BROWN ADIPOSE TISSUE FORMATION DUE TO NIVOLUMAB TREATMENT
Start Time
22:00
End Time
23:00
Ahmet Emre Eşkazan
Chronic Myeloid Leukemia
*Scientific Chair
Start Time
17:15
End Time
18:45
Chronic Myeloid Leukemia
*New Options for Patients After 1st Line
Start Time
17:15
End Time
18:45
Thierry Facon
Multiple Myeloma
*What is the Best Treatment Sequence for RRMM?
Start Time
14:00
End Time
15:30
Ahmet Burhan Ferhanoğlu
Abbvie Satellite Symposium
*Scientific Chair
Start Time
13:30
End Time
14:15
Aggressive Lymphomas
*Scientific Chair
Start Time
20:00
End Time
21:30
Andres Ferreri
Aggressive Lymphomas
*Primary CNS Lymphoma
Start Time
20:00
End Time
21:30
Ayşe Tülin Fıratlı Tuğlular
Amgen Satellite Symposium
*Scientific Chair
Start Time
21:00
End Time
21:45
Francesca Gay
Multiple Myeloma
*Is MRD the New Outcome in Clinical Practice?
Start Time
14:00
End Time
15:30
Monica Gramatges
Pediatric Leukemias-II
*Early Aging, Chronic Conditions and Biological Indicators of Aging in Childhood Acute Lymphoblastic Leukemia Survivors
Start Time
17:15
End Time
18:45
Adalet Meral Güneş
INFECTION/QUALITY OF LIFE
*Scientific Chair
Start Time
22:00
End Time
23:00
Günhan Gürman
Off the Shelf Cellular Therapies
*Scientific Chair
Start Time
10:00
End Time
11:15
İhsan Gürsel
Turkey
COVID-19 and Immunity
*From Exosome Cancer Immunotherapy to COVID-19 Specıfıc VLP Vaccine Development
Start Time
08:30
End Time
09:45
Serkan Güven
LEUKEMIA/LYMPHOMA
*CLINICAL OUTCOMES AND TREATMENT PATTERNS OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA:MULTICENTER RETROSPECTIVE ANALYSIS
Start Time
22:00
End Time
23:00
Michael Hallek
Chronic Lymphocytic Leukemia
*Scientific Chair
Start Time
11:30
End Time
13:00
Chronic Lymphocytic Leukemia
*State-of-the Art First Line Therapy of CLL
Start Time
11:30
End Time
13:00
Abbvie Satellite Symposium
*The Evolving Role of Venetoclax in the Era of Novel R/R CLL Therapies
Start Time
13:30
End Time
14:15
Volkan Hazar
Pediatric Leukemias-II
*Scientific Chair
Start Time
17:15
End Time
18:45
Dieter Hoelzer
Acute Lymphoblastic Leukemia
*Scientific Chair
Start Time
18:00
End Time
19:30
Acute Lymphoblastic Leukemia
*Immunotherapies in B-Lineage ALL
Start Time
18:00
End Time
19:30
Inna Kamaeva
INFECTION/QUALITY OF LIFE
*ASSESSMENT OF POSSIBLE RISK FACTORS FOR THE DEVELOPMENT OF CORONAVIRUS INFECTION IN PATIENTS WITH HEMATOLOGICAL CANCERS
Start Time
22:00
End Time
23:00
Kala Kamdar
Pediatric Leukemias-II
*Obesity and Metabolic Syndrome in Childhood Acute Lymphoblastic Leukemia Survivors
Start Time
17:15
End Time
18:45
Aylin Fatma Karataş
MULTIPLE MYELOMA
*PACE-LIKE REGIMENS IN THE TREATMENT OF RELAPSED/ REFRACTORY MULTIPLE MYELOMA
Start Time
22:00
End Time
23:00
Taha Kars
LYMPHOMA
*THE EFFECT OF THE CELL OF ORIGIN USING HANS ALGORITHM ON PROGNOSIS IN DIFFUSE LARGE B CELL LYMPHOMAS
Start Time
22:00
End Time
23:00
Leylagül Kaynar
Opening Ceremony
Start Time
13:30
End Time
13:45
Eva Kimby
Indolent Lymphomas
*Scientific Chair
Start Time
19:15
End Time
20:45
Indolent Lymphomas
*Follicular Lymphoma with Focus on Therapy
Start Time
19:15
End Time
20:45
Ekin Kırcalı
MULTIPLE MYELOMA
*PATIENT RELATED FACTORS OVERRIDE LENALIDOMIDE MAINTENANCE AS A FACTOR OF SEVERITY FOR COVID-19 INFECTION
Start Time
22:00
End Time
23:00
PRECLINIC/GENETIC
*PHENOTYPES OF BONE MARROW MONOCYTES IN STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA: A DESCRIPTIVE PILOT STUDY
Start Time
22:00
End Time
23:00
Ebru Koca
LYMPHOMA
*Scientific Chair
Start Time
22:00
End Time
23:00
Derya Koyun
LYMPHOMA
*PRIMARY GASTRIC NK/T CELL LYMPHOMA WITH T CELL PHENOTYPE: A RARE EBV RELATED LOCALLY INVOLVED AGRESSIVE LYMPHOMA CASE.
Start Time
22:00
End Time
23:00
Reyhan Küçükkaya
Opening Ceremony
Start Time
13:30
End Time
13:45
Alphan Küpesiz
PRECLINIC/GENETIC
*Scientific Chair
Start Time
22:00
End Time
23:00
Meltem Kurt Yüksel
Opening Ceremony
Start Time
13:30
End Time
13:45
Erdal Kurtoğlu
Janssen Satellite Symposium
*New Dimension in Efficacy: Darzalex in RRMM
Start Time
16:00
End Time
16:45
Joseph Mikhael
Amgen Satellite Symposium
*Carfilzomib Treatment in Relapsed/Refractory Multiple Myeloma
Start Time
21:00
End Time
21:45
Yaşa Gül Mutlu
PRECLINIC/GENETIC
*MUTATION PROFILE OF THE PATIENTS TESTED WITH NEXT GENERATION SEQUENCING AND CLINICAL IMPLICATIONS
Start Time
22:00
End Time
23:00
LYMPHOMA
*IS SURGICAL EXCISIONAL BIOPSY STILL THE GOLD STANDARD DIAGNOSTIC APPROACH IN LYMPHOMAS?
Start Time
22:00
End Time
23:00
Mehmet Fatih Okçu
Pediatric Leukemias-II
*Scientific Chair
Start Time
17:15
End Time
18:45
Pediatric Leukemias-II
*Epidemiology of Late Effects in Children with Acute Lymphoblastic Leukemia
Start Time
17:15
End Time
18:45
Hale Ören
Pediatric Leukemias-I
*Scientific Chair
Start Time
14:00
End Time
15:30
Oliver Ottmann
Acute Lymphoblastic Leukemia
*Progress in Ph+/Ph-like ALL
Start Time
18:00
End Time
19:30
Düzgün Özatlı
LEUKEMIA/LYMPHOMA
*Scientific Chair
Start Time
22:00
End Time
23:00
Muhit Özcan
Hodgkin Lymphoma
*Scientific Chair
Start Time
14:45
End Time
16:15
Fahir Özkalemkaş
MULTIPLE MYELOMA
*Scientific Chair
Start Time
22:00
End Time
23:00
Güner Hayri Özsan
3rd Istanbul Immunohematology Summit
*Opening Remarks
Start Time
08:00
End Time
08:15
Opening Ceremony
Start Time
13:30
End Time
13:45
Şule Mine Öztürk
LYMPHOMA
*Scientific Chair
Start Time
22:00
End Time
23:00
Mehmet Sezgin Pepeler
INFECTION/QUALITY OF LIFE
*OUR CENTER EXPERIENCE OF MULTIPLE MYELOMA PATIENTS WITH COVID-19
Start Time
22:00
End Time
23:00
Alexander Popov
Pediatric Leukemias-I
*FLOW-MRD in the Era of BITE & CART Therapies
Start Time
14:00
End Time
15:30
Davide Rossi
Chronic Lymphocytic Leukemia
*Management of Relapsed CLL and Richter Transformation
Start Time
11:30
End Time
13:00
Susanne Saussele
Chronic Myeloid Leukemia
*Scientific Chair
Start Time
17:15
End Time
18:45
Chronic Myeloid Leukemia
*Treatment Free Remission. A Goal for All CML Patients?
Start Time
17:15
End Time
18:45
Ömür Gökmen Sevindik
Multiple Myeloma
*Scientific Chair
Start Time
14:00
End Time
15:30
Janssen Satellite Symposium
*New Dimension in Efficacy: Darzalex in RRMM
Start Time
16:00
End Time
16:45
Pieter Sonneveld
Multiple Myeloma
*Scientific Chair
Start Time
14:00
End Time
15:30
Multiple Myeloma
*Antibodies Upfront or at Relapse?
Start Time
14:00
End Time
15:30
Marion Subklewe
Aggressive Lymphomas
*CAR T-Cells in DLBCL
Start Time
20:00
End Time
21:30
Tolga Sütlü
Turkey
Off the Shelf Cellular Therapies
*NK Cells
Start Time
10:00
End Time
11:15
Feyzi İlhan Tezcan
COVID-19 and Immunity
*Scientific Chair
Start Time
08:30
End Time
09:45
Catherine Thieblemont
Indolent Lymphomas
*Management of Marginal Zone Lymphoma
Start Time
19:15
End Time
20:45
Mesut Tığlıoğlu
LEUKEMIA/LYMPHOMA
*ANALYSIS OF FACTORS PREDICTING EFFICACY OF IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS
Start Time
22:00
End Time
23:00
Mario Tiribelli
Chronic Myeloid Leukemia
*Modern CML Treatment According to the New ELN Recommendations
Start Time
17:15
End Time
18:45
Şule Ünal Cangül
Opening Ceremony
Start Time
13:30
End Time
13:45
Atilla Uslu
MULTIPLE MYELOMA
*THE IMPACT OF PRETRANSPLANT IMMUNOMODULATORY DRUGS ON CMV REACTIVATION
Start Time
22:00
End Time
23:00
Koen Van Besien
Indolent Lymphomas
*Cellular Therapies for Follicular Lymphoma
Start Time
19:15
End Time
20:45
Bastian Von Tresckow
Hodgkin Lymphoma
*Scientific Chair
Start Time
14:45
End Time
16:15
Hodgkin Lymphoma
*Relapsed and Refractory HL: Innovative Therapies
Start Time
14:45
End Time
16:15
Andrew Wei
Acute Myeloid Leukemia
*New Agents For The Treatment of Older Patients
Start Time
09:30
End Time
11:00
Boran Yavuz
MULTIPLE MYELOMA
*FREE LIGHT CHAIN ESCAPE IN MULTIPLE MYELOMA: IS IT AN EARLY CLUE OF AGGRESSIVE PROGRESSION?
Start Time
22:00
End Time
23:00
Mustafa Nuri Yenerel
Turkey
INFECTION/QUALITY OF LIFE
*Scientific Chair
Start Time
22:00
End Time
23:00
Şebnem Yılmaz
LEUKEMIA/LYMPHOMA
*Scientific Chair
Start Time
22:00
End Time
23:00
INFECTION/QUALITY OF LIFE
*EVALUATION OF POSSIBLE EFFECTS OF THE COVID-19 PANDEMIC ON FEBRILE NEUTROPENIA EPISODES IN CHILDREN WITH ACUTE LEUKEMIA
Start Time
22:00
End Time
23:00
LEUKEMIA/LYMPHOMA
*EVALUATION OF CLINICAL AND LABORATORY FINDINGS AT DIAGNOSIS AND RELAPSE IN CHILDREN WITH ACUTE LEUKEMIA
Start Time
22:00
End Time
23:00
Hülya Yılmaz
INFECTION/QUALITY OF LIFE
*DETERMINATION OF INFECTION FREQUENCY IN PATIENTS USING RUXOLITINIB DUE TO GRAFT VERSUS HOST DISEASE
Start Time
22:00
End Time
23:00